CN1203855C - 左西孟旦的药物溶液 - Google Patents

左西孟旦的药物溶液 Download PDF

Info

Publication number
CN1203855C
CN1203855C CNB008126453A CN00812645A CN1203855C CN 1203855 C CN1203855 C CN 1203855C CN B008126453 A CNB008126453 A CN B008126453A CN 00812645 A CN00812645 A CN 00812645A CN 1203855 C CN1203855 C CN 1203855C
Authority
CN
China
Prior art keywords
solution
levosimendan
pharmaceutically acceptable
solutions
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008126453A
Other languages
English (en)
Chinese (zh)
Other versions
CN1373665A (zh
Inventor
R·巴克斯特罗姆
P·戈兰维克
R·海卡拉
S·佩尔塔利
E·索克
R·耶尔乔拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8555263&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1203855(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Publication of CN1373665A publication Critical patent/CN1373665A/zh
Application granted granted Critical
Publication of CN1203855C publication Critical patent/CN1203855C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB008126453A 1999-09-10 2000-09-08 左西孟旦的药物溶液 Expired - Lifetime CN1203855C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI19991925 1999-09-10
FI991925A FI109659B (fi) 1999-09-10 1999-09-10 Levosimendaanin farmaseuttisia liuoksia

Publications (2)

Publication Number Publication Date
CN1373665A CN1373665A (zh) 2002-10-09
CN1203855C true CN1203855C (zh) 2005-06-01

Family

ID=8555263

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008126453A Expired - Lifetime CN1203855C (zh) 1999-09-10 2000-09-08 左西孟旦的药物溶液

Country Status (39)

Country Link
US (2) US6730673B1 (https=)
EP (1) EP1210085B1 (https=)
JP (1) JP4708648B2 (https=)
KR (1) KR100869752B1 (https=)
CN (1) CN1203855C (https=)
AR (1) AR025449A1 (https=)
AT (1) ATE315937T1 (https=)
AU (1) AU771027B2 (https=)
BG (1) BG65827B1 (https=)
BR (1) BRPI0013924B8 (https=)
CA (1) CA2382013C (https=)
CO (1) CO5180582A1 (https=)
CZ (1) CZ303095B6 (https=)
DE (1) DE60025627T2 (https=)
DK (1) DK1210085T3 (https=)
EA (1) EA005067B1 (https=)
EE (1) EE05375B1 (https=)
ES (1) ES2256034T3 (https=)
FI (1) FI109659B (https=)
HK (1) HK1049282B (https=)
HR (1) HRP20020298B1 (https=)
HU (1) HU228340B1 (https=)
IL (2) IL148379A0 (https=)
IS (1) IS2244B (https=)
ME (1) ME00523B (https=)
MX (1) MXPA02002423A (https=)
MY (1) MY125984A (https=)
NO (1) NO331989B1 (https=)
NZ (1) NZ517605A (https=)
PL (1) PL202356B1 (https=)
PT (1) PT1210085E (https=)
RS (1) RS50445B (https=)
SI (1) SI1210085T1 (https=)
SK (1) SK287154B6 (https=)
TR (1) TR200200620T2 (https=)
TW (1) TWI242434B (https=)
UA (1) UA73954C2 (https=)
WO (1) WO2001019334A2 (https=)
ZA (1) ZA200201828B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
CN100428937C (zh) * 2003-10-30 2008-10-29 北京海合天科技开发有限公司 左西孟旦冷冻干燥组合物
CN100367964C (zh) * 2004-04-29 2008-02-13 王思清 左西孟旦-β环糊精包含物制剂
JP2008530186A (ja) * 2005-02-18 2008-08-07 オリオン コーポレーション 心不全治療法
JP2010514778A (ja) * 2006-12-28 2010-05-06 オリオン コーポレーション 非経口投与のためのレボシメンダン製剤
US10046081B2 (en) 2008-04-11 2018-08-14 The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. Electrospun dextran fibers and devices formed therefrom
WO2012093404A2 (en) 2011-01-03 2012-07-12 Gufic Biosciences Limited Parenteral formulations of levosimendan
US8697118B2 (en) * 2011-10-18 2014-04-15 St. Teresa Medical, Inc. Stabilizers for hemostatic products
US9808529B2 (en) * 2012-05-18 2017-11-07 Luoda Pharma Pty Ltd Liquid formulation
CN105106113B (zh) * 2015-09-30 2019-07-26 济南康和医药科技有限公司 一种左西孟旦注射液及其制备方法
LT3370693T (lt) * 2015-11-06 2020-04-10 Carinopharm Gmbh Patobulintos levosimendano vaisto formos, skirtos intraveniniam įvedimui, tokiam kaip infuzija ar injekcija, ir infuzijos koncentratas
US10828387B2 (en) 2015-11-12 2020-11-10 St. Teresa Medical, Inc. Method of sealing a durotomy
CN108261398A (zh) * 2016-12-30 2018-07-10 齐鲁制药有限公司 一种含有左西孟旦的供注射用药物制剂及其制备方法
US10953128B2 (en) 2017-11-02 2021-03-23 St. Teresa Medical, Inc. Fibrin sealant products
CN111474289A (zh) * 2019-10-31 2020-07-31 武汉嘉诺康医药技术有限公司 一种利用反相色谱分离分析左西孟旦中右西孟旦的方法
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
CN111514147B (zh) * 2020-05-12 2021-09-17 成都欣捷高新技术开发股份有限公司 用于急性失代偿心力衰竭症状的左西孟旦钠药用组合物及制备方法
US11760730B2 (en) 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan
TR2021013305A2 (tr) * 2021-08-23 2023-03-21 Tuem Ekip Ilac Anonim Sirketi Li̇yofi̇li̇ze levosi̇mendan formülasyonlari
CN115518037A (zh) * 2022-10-14 2022-12-27 上药东英（江苏）药业有限公司 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法
CN116473930B (zh) * 2023-05-17 2023-12-15 山东泰合医药科技有限公司 一种注射用左西孟旦及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
GB9606474D0 (en) 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia

Also Published As

Publication number Publication date
HK1049282A1 (en) 2003-05-09
JP2003509351A (ja) 2003-03-11
JP4708648B2 (ja) 2011-06-22
CO5180582A1 (es) 2002-07-30
DE60025627D1 (de) 2006-04-06
CA2382013C (en) 2009-08-11
HUP0202749A3 (en) 2003-03-28
MY125984A (en) 2006-09-29
ZA200201828B (en) 2003-08-27
HK1049282B (zh) 2005-12-30
TR200200620T2 (tr) 2002-09-23
FI109659B (fi) 2002-09-30
PL202356B1 (pl) 2009-06-30
US6943164B2 (en) 2005-09-13
BR0013924A (pt) 2002-05-21
CZ303095B6 (cs) 2012-03-28
US6730673B1 (en) 2004-05-04
SI1210085T1 (sl) 2006-04-30
PT1210085E (pt) 2006-05-31
CA2382013A1 (en) 2001-03-22
AU7004400A (en) 2001-04-17
HU228340B1 (en) 2013-03-28
SK3272002A3 (en) 2002-12-03
ME00523B (me) 2011-10-10
TWI242434B (en) 2005-11-01
NO20021090L (no) 2002-03-05
EA005067B1 (ru) 2004-10-28
US20040106617A1 (en) 2004-06-03
BG106589A (bg) 2002-11-29
BG65827B1 (bg) 2010-02-26
BR0013924B1 (pt) 2013-09-24
CZ2002788A3 (cs) 2002-11-13
ATE315937T1 (de) 2006-02-15
KR20020048400A (ko) 2002-06-22
IS6296A (is) 2002-03-06
HRP20020298B1 (hr) 2007-02-28
BRPI0013924B8 (pt) 2021-05-25
DK1210085T3 (da) 2006-05-08
YU16902A (sh) 2004-09-03
EA200200348A1 (ru) 2002-08-29
KR100869752B1 (ko) 2008-11-21
HRP20020298A2 (en) 2003-06-30
HUP0202749A2 (hu) 2003-02-28
MXPA02002423A (es) 2002-08-12
AU771027B2 (en) 2004-03-11
NZ517605A (en) 2003-08-29
EP1210085A2 (en) 2002-06-05
CN1373665A (zh) 2002-10-09
NO20021090D0 (no) 2002-03-05
NO331989B1 (no) 2012-05-21
AR025449A1 (es) 2002-11-27
UA73954C2 (uk) 2005-10-17
EE200200129A (et) 2003-04-15
RS50445B (sr) 2010-03-02
WO2001019334A2 (en) 2001-03-22
IS2244B (is) 2007-05-15
EE05375B1 (et) 2011-02-15
IL148379A (en) 2006-12-10
PL354028A1 (pl) 2003-12-15
WO2001019334A3 (en) 2001-11-15
SK287154B6 (sk) 2010-01-07
EP1210085B1 (en) 2006-01-18
IL148379A0 (en) 2002-09-12
DE60025627T2 (de) 2006-11-16
ES2256034T3 (es) 2006-07-16
FI19991925L (fi) 2001-03-10

Similar Documents

Publication Publication Date Title
CN1203855C (zh) 左西孟旦的药物溶液
CN1246039C (zh) 莫西沙星/氯化钠制剂
CN1612737A (zh) 铂衍生物药物制剂
CN1809376A (zh) 装在药物容器中的稳定的液体蛋白质制剂
CN106061467A (zh) 用于产生去甲肾上腺素的稳定低浓度、可注射溶液的方法
CN1686116A (zh) 左旋奥硝唑的静脉给药制剂及其制备方法
CN1708270A (zh) 丙泊酚与半胱氨酸
CN1897940A (zh) 用于非经肠胃给药的长春氟宁医药组合物及其制备方法和用途
WO2002007724A1 (en) FREEZE-DRIED PREPARATION OF N-[o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME
HK1050318A1 (zh) 多剂量红细胞生成素制剂
JP2000219628A (ja) アラトロフロキサシンの予め混合した注射用組成物
CN1870974B (zh) 注射用加巴喷丁组合物的生产方法
CN1857729A (zh) 含新鱼腥草素钠和Solutol HS15的药物组合物
JP2010528025A (ja) ベンジルアルコールとの多用量濃縮エスモロール
CN1611219A (zh) 左西孟旦药物组合物及其制备方法
WO2015183213A1 (en) Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid
EP1178798A1 (en) Parenteral formulation of 5-(2-chloroethyl)-4-methylthiazole edisylate(clomethiazole edisylate)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050601